Janus Henderson Group PLC Boosts Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

Janus Henderson Group PLC grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,799,352 shares of the company’s stock after purchasing an additional 355,685 shares during the period. Janus Henderson Group PLC owned 7.10% of Perspective Therapeutics worth $64,014,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the third quarter valued at approximately $57,000. US Bancorp DE increased its stake in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics in the second quarter worth $117,000. Point72 DIFC Ltd bought a new stake in shares of Perspective Therapeutics in the second quarter worth $118,000. Finally, Intech Investment Management LLC acquired a new position in Perspective Therapeutics in the third quarter worth $137,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Up 0.3 %

CATX stock opened at $3.72 on Friday. Perspective Therapeutics, Inc. has a one year low of $2.28 and a one year high of $19.05. The firm has a 50-day moving average of $9.93 and a two-hundred day moving average of $12.00.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million during the quarter. As a group, equities research analysts predict that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CATX. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer reduced their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, November 25th. Finally, Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Perspective Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $15.14.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor purchased 14,500 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jonathan Robert Hunt purchased 12,829 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The stock was bought at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the transaction, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. This represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 41,595 shares of company stock valued at $156,785. 3.52% of the stock is currently owned by corporate insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.